A Genome Engineering Breakthrough
B-MoGen is the first in the world to engineer the mitochondria genome
At B-MoGen Biotechnologies we are paving the way toward precise mitochondrial gene editing.
Problem: Mitochondrial Diseases are Currently Incurable
Mitochondrial disease refers to a group of chronic genetic disorders that affect the mitochondria (an organelle found in large numbers in cells throughout the body that is largely responsible for generating the energy we use). Mitochondrial disease can look like many well-known diseases like Parkinson’s, Alzheimer’s, Autism and several others.
Mitochondrial diseases are currently incurable but new techniques are being tested in mice that could then be tested in clinical trials with patients.
None of the recent advancements in gene editing have been able to precisely edit the mitochondrial genome. The difficulty with Mitochondrial DNA editing is that it has not been possible to make targeted gene knockouts in the mitochondrial genome until now.
Solution: B-MoGen Mitochondrial Gene Editing Technology
At B-MoGen, we are using the our mitochondrial gene editing technology to generate a set of tools and reagents to create human and mouse cell lines that carry a deletion in each protein and ribosomal RNA encoded on the mitochondrial genome. This technology provides researchers a new and novel set of tools that enables them to better understand and investigate mitochondria biology and associated diseases.
- B-MoGen is first in the world to engineer the mitochondrial DNA in human cells
- B-MoGen has an exclusive license to this technology